Should the patent system for new medicines be abolished?
Repository Usage Stats
Orphan Drug Production
Patents as Topic
Published Version (Please cite this version)10.1038/sj.clpt.6100393
Publication InfoDiMasi, JA; & Grabowski, HG (2007). Should the patent system for new medicines be abolished?. Clin Pharmacol Ther, 82(5). pp. 488-490. 10.1038/sj.clpt.6100393. Retrieved from https://hdl.handle.net/10161/6721.
This is constructed from limited available data and may be imprecise. To cite this article, please review & use the official citation provided by the journal.
More InfoShow full item record
Professor Emeritus of Economics
Professor Grabowski specializes in the investigation of economics in the pharmaceutical industry, government regulation of business, and the economics of innovation. His specific interests within these fields include intellectual property and generic competition issues, the effects of government policy actions, and the costs and returns to pharmaceutical R&D. He has been publishing research papers for over four decades, from his earlier work, “The Effects of Regulatory Policy on the Incentives